<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bamlanivimab (United States: Authorization withdrawn): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bamlanivimab (United States: Authorization withdrawn): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bamlanivimab (United States: Authorization withdrawn): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="130065" href="/d/html/130065.html" rel="external">see "Bamlanivimab (United States: Authorization withdrawn): Patient drug information"</a> and <a class="drug drug_general" data-topicid="130072" href="/d/html/130072.html" rel="external">see "Bamlanivimab (United States: Authorization withdrawn): Drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F55024450"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F55017070"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f2cd662-970c-4405-bbca-4a27559f302b">COVID-19, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, mild to moderate: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to concerns of decreased susceptibility among SARS-CoV-2 variants, the FDA revoked the emergency use authorization (EUA) for bamlanivimab monotherapy in the United States effective April 16, 2021 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2'])">Ref</a></span>). Circulating SARS-CoV-2 variants may be associated with resistance to bamlanivimab; there is a potential risk of treatment failure. Bamlanivimab is only for use in patients who are at high-risk of progression to severe disease or hospitalization; refer to <a href="/external-redirect?target_url=https%3A%2F%2Fcovid-vaccine.canada.ca%2Finfo%2Fpdf%2Fbamlanivimab-pm1-en.pdf&amp;token=oJf38znziMCSlfQ2EYYiDkmPtyUAauZM%2Brl%2BEvKENfNgVE1pTVv%2FU6uf%2BXp%2BX5I7APjCLTAztqlIOVbI3VmxibjvH04oCNYnYVcdu2atj8Q%3D&amp;TOPIC_ID=130087" target="_blank">Canadian product monograph</a> for more information on patients at high risk for progression to severe disease. Bamlanivimab should NOT be used in patients who are hospitalized due to severe COVID-19 respiratory disease or in patients with COVID-19 requiring high flow oxygen or mechanical ventilation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Health Canada interim order: </i>Children ≥12 years and Adolescents weighing ≥40 kg: IV: 700 mg as a single dose; administer as soon as possible after a positive SARS-CoV-2 test and within 10 days of symptom onset. <b>Note: </b>Bamlanivimab has not been studied in pediatric patients; Health Canada's interim order for use in pediatric patients ≥12 years of age weighing ≥40 kg is based on likelihood of exposures similar to adults.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55017073"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided (has not been studied); however, renal impairment is not expected to affect bamlanivimab exposure.</p></div>
<div class="block dohp drugH1Div" id="F55017074"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F55016751"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="130072" href="/d/html/130072.html" rel="external">see "Bamlanivimab (United States: Authorization withdrawn): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f2cd662-970c-4405-bbca-4a27559f302b">COVID-19, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, mild to moderate (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to concerns of decreased susceptibility among SARS-CoV-2 variants, the FDA revoked the emergency use authorization (EUA) for bamlanivimab monotherapy in the United States effective April 16, 2021 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2'])">Ref</a></span>). However, bamlanivimab may still be available in Canada. Reserve for patients with positive SARS-CoV-2 direct viral testing who are at high risk for progression to severe disease or hospitalization; refer to Canadian product monograph for more information on patients at high risk for progression to severe disease. Use is <b>not</b> authorized for patients who are hospitalized or require new or increased oxygen therapy due to COVID-19; outcomes may be worse if used in patients requiring high-flow oxygen or mechanical ventilation. Consider local prevalence of SARS-CoV-2 variants when evaluating treatment options.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: Weight ≥40 kg: </b>700 mg as a single dose; administer as soon as possible after a positive SARS-CoV-2 test and within 10 days of symptom onset.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55016753"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided (has not been studied); however, renal impairment is not expected to affect the exposure of bamlanivimab.</p></div>
<div class="block doha drugH1Div" id="F55016754"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F55189734"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity and infusion related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reactions</b>, including <b>anaphylaxis,</b> and <b>infusion related reactions</b>, have been reported with bamlanivimab. Patients may experience altered mental status, angioedema, asthenia, bronchospasm, cardiac arrhythmia (including atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, chills, diaphoresis, <b>dizziness</b>, dyspnea, fatigue, fever, <b>headache</b>, hypertension, hypotension, myalgia, nausea, <b>pruritus</b>, rash (including urticaria), reduced oxygen saturation, and throat irritation with infusion related reactions, but most reactions were mild in severity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33113295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33113295'])">Ref</a></span>). Slower infusion rates may be considered. All reactions were reversible; severe reactions required discontinuation and treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Rapid; most infusion related reactions occurred during infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33113295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33113295'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55024179"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from the original FDA issued emergency use authorization (EUA) (FDA 2021a). <b>However, the FDA revoked the EUA for bamlanivimab monotherapy in the United States effective April 16, 2021</b> (FDA 2021b).</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2%)<span class="lexi-table-link-container"> (<a aria-label="Pruritus table link" class="lexi-table-link" data-table-id="lexi-content-pruritus" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pruritus')">table 1</a>)</span><span class="table-link" style="display:none;">Pruritus</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pruritus" frame="border" id="lexi-content-pruritus" rules="all">
<caption style="text-align:center;">
<b>Bamlanivimab: Adverse Reaction: Pruritus</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Bamlanivimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Bamlanivimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">700 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">COVID-19, mild to moderate</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">156</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">FDA 2021a</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2%; including type 1 hypersensitivity reaction, flushing, and facial swelling)<span class="lexi-table-link-container"> (<a aria-label="Hypersensitivity Reaction table link" class="lexi-table-link" data-table-id="lexi-content-hypersensitivity-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypersensitivity-reaction')">table 2</a>)</span><span class="table-link" style="display:none;">Hypersensitivity Reaction</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypersensitivity Reaction" frame="border" id="lexi-content-hypersensitivity-reaction" rules="all">
<caption style="text-align:center;">
<b>Bamlanivimab: Adverse Reaction: Hypersensitivity Reaction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Bamlanivimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Bamlanivimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">COVID-19, mild to moderate</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">309</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">156</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">FDA 2021a</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 3</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, headache (3%)<span class="lexi-table-link-container"> (<a aria-label="Headache table link" class="lexi-table-link" data-table-id="lexi-content-headache" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache')">table 4</a>)</span><span class="table-link" style="display:none;">Headache</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Bamlanivimab: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Bamlanivimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Bamlanivimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">700 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">COVID-19, mild to moderate</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">156</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">FDA 2021a</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache" frame="border" id="lexi-content-headache" rules="all">
<caption style="text-align:center;">
<b>Bamlanivimab: Adverse Reaction: Headache</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Bamlanivimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Bamlanivimab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">700 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">COVID-19, mild to moderate</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">156</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">FDA 2021a</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction (including severe infusion related reaction)</p></div>
<div class="block coi drugH1Div" id="F55362985"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to bamlanivimab or any component of the formulation or container.</p></div>
<div class="block war drugH1Div" id="F55016721"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Antiviral resistance: Development of SARS-CoV-2 variants that are resistant to bamlanivimab may increase risk of treatment failure; use of bamlanivimab alone should only be considered if other monoclonal antibodies that retain neutralization activity against prevalent variants are not available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Clinical worsening: Clinical worsening of COVID-19, including signs or symptoms of altered mental status, arrhythmia (atrial fibrillation, bradycardia, tachycardia), fatigue, fever, hypoxia, or increased respiratory difficulty, has been reported in the 24 hours after administration of bamlanivimab; some of these events required hospitalization. It is not known if these events were related to bamlanivimab.</p>
<p style="text-indent:-2em;margin-left:4em;">• Limitations of use: Bamlanivimab is not authorized for use in patients who are hospitalized due to COVID-19, require oxygen therapy due to COVID-19, or require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity. Benefit of treatment has not been observed in patients hospitalized due to COVID-19 (Lundgren 2020). Monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen therapy or mechanical ventilation.</p></div>
<div class="block prod-avail drugH1Div" id="F55005990"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Investigational agent; approved under interim authorization by Health Canada November 2020.</p></div>
<div class="block foc drugH1Div" id="F55049298"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Bamlanivimab 700 mg/20 mL (20 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F55049297"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F55195459"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Bamlanivimab Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">700 mg/20 mL (per mL): $0.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55049301"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Bamlanivimab 700 mg/20 mL ([DSC])</p></div>
<div class="block accres drugH1Div" id="F55016715"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">The distribution of bamlanivimab alone has stopped as of March 24, 2021 in response to the sustained increase in SARS-CoV-2 viral variants in the United States that are resistant to bamlanivimab administered alone as well as the availability of other authorized monoclonal antibody therapies that are expected to retain activity to these variants. All treatment delivery sites will continue to be able to order bamlanivimab and etesevimab, to be administered together, from the authorized distributer following existing ordering and reporting procedures. Additionally, sites can order etesevimab alone to pair with the current supply of bamlanivimab the site has available. Sites of care can submit requests for etesevimab directly to AmerisourceBergen via C19 Therapies Direct Order Request (http://www.smartsheet.com); for more information visit: https://app.smartsheet.com/b/form/255d164d67834793b4ab549e160941e8.</p></div>
<div class="block admp drugH1Div" id="F55017076"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Must be diluted prior to administration. If diluted solution is refrigerated following preparation, allow solution to come to room temperature (~20 minutes) prior to administration. Administer as an IV infusion over ≥60 minutes. Administer through a PVC or polyethylene-lined PVC infusion set containing a 0.2 or 0.22 micron in-line or add-on polyethersulfone filter. Entire infusion solution in the bag should be administered; flush line with NS following completion of infusion to ensure entire dose is administered. Slow or interrupt infusion and treat as appropriate if the patient develops any signs of infusion-related reaction (eg, urticaria, pruritus, rash, swelling of the face, chest discomfort); if severe or life-threatening hypersensitivity reactions occur, immediately discontinue infusion and initiate appropriate medications and/or supportive care.</p></div>
<div class="block adm drugH1Div" id="F55016755"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Must be diluted prior to administration. If diluted solution is refrigerated following preparation, allow solution to come to room temperature (~20 minutes) prior to administration. Administer as an IV infusion over ≥60 minutes. Administer through a PVC or polyethylene-lined PVC infusion set containing a 0.2 or 0.22 micron in-line polyethersulfone filter. Slow or stop infusion and treat as appropriate if an infusion-related reaction occurs. Flush infusion line with NS following completion of infusion.</p></div>
<div class="block sts drugH1Div" id="F55016748"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials at 2°C to 8°C (36°F to 46°F); protect from light. Do not freeze, shake, or expose to direct light or heat.</p>
<p style="text-indent:-2em;margin-left:2em;">Diluted infusion solution should be administered immediately. If immediate administration is not possible, store diluted bamlanivimab infusion solution for up to 48 hours refrigerated at 2°C to 8°C (36°F to 46°F) or up to 14 hours at 20°C to 25°C (68°F to 77°F) including infusion time. If refrigerated, allow infusion solution to warm to room temperature for ~20 minutes prior to administration.</p></div>
<div class="block usep drugH1Div" id="F55017066"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> No longer authorized for use in the United States; due to concerns of decreased susceptibility among SARS-CoV-2 variants, the FDA revoked the emergency use authorization (EUA) for bamlanivimab monotherapy in the United States effective April 16, 2021 (FDA 2021b).</p>
<p style="text-indent:0em;margin-top:2em;">Health Canada interim order: Investigational agent for treatment of mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 illness and/or hospitalization (Health Canada issued interim order for use in ages ≥12 years weighing ≥40 kg and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">A high-risk patient is a person with ≥1 of the following:</p>
<p style="text-indent:-2em;margin-left:4em;">• BMI ≥35 (if ≥18 years of age)</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic kidney disease</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression (due to treatment or underlying disease)</p>
<p style="text-indent:-2em;margin-left:4em;">• Age ≥65 years</p>
<p style="text-indent:-2em;margin-left:4em;">• Age ≥55 years AND have ≥1 of the following:</p>
<p style="text-indent:-2em;margin-left:6em;">- Cardiovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">- Hypertension</p>
<p style="text-indent:-2em;margin-left:6em;">- Chronic respiratory disease (including chronic obstructive pulmonary disease)</p>
<p style="text-indent:-2em;margin-left:4em;">• Age 12 to 17 years AND have ≥1 of the following:</p>
<p style="text-indent:-2em;margin-left:6em;">- BMI ≥85th percentile for age and gender</p>
<p style="text-indent:-2em;margin-left:6em;">- Sickle cell disease</p>
<p style="text-indent:-2em;margin-left:6em;">- Congenital or acquired heart disease</p>
<p style="text-indent:-2em;margin-left:6em;">- Neurodevelopmental disorders (eg, cerebral palsy)</p>
<p style="text-indent:-2em;margin-left:6em;">- Medical-related technological dependence (eg, tracheostomy, gastrostomy, positive pressure ventilation [not related to COVID-19])</p>
<p style="text-indent:-2em;margin-left:6em;">- Reactive airway or other chronic respiratory disease that requires daily medication for control (eg, asthma)</p>
<p style="text-indent:-2em;margin-left:2em;">Bamlanivimab should NOT be used in patients who are hospitalized due to severe COVID-19 respiratory disease or in patients with COVID-19 requiring high flow oxygen or mechanical ventilation.</p></div>
<div class="block mst drugH1Div" id="F55430672"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Bamlanivimab may be confused with belimumab</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55024541"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55024538"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55016719"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">The emergency use authorization for bamlanivimab monotherapy in the United States has been revoked (FDA 2021b). The original bamlanivimab clinical trials required male and female patients of reproductive potential to use effective contraception during the study (Gottlieb 2021).</p></div>
<div class="block pri drugH1Div" id="F55016718"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The emergency use authorization for bamlanivimab monotherapy in the United States has been revoked (FDA 2021b). Nonclinical reproductive toxicity studies have not been conducted (FDA 2021a).</p>
<p style="text-indent:0em;margin-top:2em;">Bamlanivimab is a humanized monoclonal antibody (IgG<sub>1</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009). The potential benefits or risks of in utero exposure to bamlanivimab to the fetus are not known (FDA 2021a).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of severe illness from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID. Symptomatic pregnant patients may require ICU admission, mechanical ventilation, or ventilatory support (ECMO) compared to symptomatic nonpregnant patients. Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG 2023; NIH 2022).</p>
<p style="text-indent:0em;margin-top:2em;">The original clinical trials of bamlanivimab did not include persons who were pregnant (Gottlieb 2021). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor maternal and infant outcomes following exposure to COVID-19 during pregnancy is ongoing. Health care providers are encouraged to enroll patients exposed to COVID-19 during pregnancy in the Organization of Teratology Information Specialists pregnancy registry (1-877-311-8972; https://mothertobaby.org/join-study/).</p></div>
<div class="block mopp drugH1Div" id="F55017077"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for infusion-related reactions (eg, urticaria, pruritus, rash, swelling of the face, chest discomfort) and hypersensitivity/anaphylaxis during and after infusion.</p></div>
<div class="block pha drugH1Div" id="F55016750"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bamlanivimab is a recombinant neutralizing human IgG1k monoclonal antibody to the spike protein of SARS-CoV-2. Bamlanivimab binds to the spike protein, blocking attachment to the human ACE2 receptor.</p></div>
<div class="block phksp drugH1Div" id="F55017067"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Clinical trials have not been performed; serum exposures in patients ≥12 years of age and weighing ≥40 kg are expected to be similar to those observed in adults based on pharmacokinetic modeling.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed January 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bamlanivimab for injection [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32338708">
<a name="32338708"></a>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. <i>Clin Infect Dis</i>. 2020:ciaa478. doi:10.1093/cid/ciaa478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/32338708/pubmed" id="32338708" target="_blank">32338708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33113295">
<a name="33113295"></a>Chen P, Nirula A, Heller B, et al; BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. <i>N Engl J Med</i>. 2020. doi:10.1056/NEJMoa2029849<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33113295/pubmed" id="33113295" target="_blank">33113295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33475701">
<a name="33475701"></a>Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. <i>JAMA</i>. 2021;325(7):632-644. doi:10.1001/jama.2021.0202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33475701/pubmed" id="33475701" target="_blank">33475701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33356051">
<a name="33356051"></a>Lundgren JD, Grund B, Barkauskas CE, et al; ACTIV-3/TICO LY-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. <i>N Engl J Med</i>. Published online December 22, 2020. doi:10.1056/NEJMoa2033130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33356051/pubmed" id="33356051" target="_blank">33356051</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated May 13, 2022. Accessed May 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:0.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bamlanivimab-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab. http://pi.lilly.com/eua/bamlanivimab-eua-factsheet-hcp.pdf. Updated March 18, 2021a. Accessed March 19, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>US Food and Drug Administration (FDA). Emergency use authorization 090 revocation. Revocation Letter Bamlanivimab 04162021. <a href="https://www.fda.gov/media/147629/download" target="_blank">https://www.fda.gov/media/147629/download</a>. Published April 16, 2021b. Accessed April 19, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 130087 Version 66.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
